Sisram Medical (HKG:1696) said its sublicensed-in botulinum toxin type A for injection passed the quality testing from China's National Institutes for Food and Drug Control, according to a Monday Hong Kong bourse filing.
The product is indicated for a temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscles activity in adult patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.